Enfortumab vedotin

You have access
Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report
HIROKI BAMBA, SATOSHI YAMAMOTO, KEITA HIGA, KOICHIRO KUROKAWA, SANJI KANAOKA and KAZUYOSHI NAKAMURA

Anticancer Research March 2026, 46 (3) 1747-1753; DOI: https://doi.org/10.21873/anticanres.18069
You have access
Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan
YUKI KOBARI, JUNPEI IIZUKA, HANAE KONDO, MAKIKO ICHIOKA, SHUN WATANABE, KAZUTAKA NAKAMURA, YUKI NEMOTO, TOSHIHIDE HORIUCHI, SHINSUKE MIZOGUCHI, KAZUHIKO YOSHIDA, HIROAKI SHIMMURA, YASUNOBU HASHIMOTO, TSUNENORI KONDO, HIROSHI KOBAYASHI and TOSHIO TAKAGI

Anticancer Research December 2025, 45 (12) 5645-5654; DOI: https://doi.org/10.21873/anticanres.17898
You have access
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma
KYOSUKE NISHIO, KENSUKE HIROSUNA, TAIZO UCHIMOTO, HEIMA NIIGAWA, SHO KAKUMAE, TAISUKE JO, HIROFUMI MORINAKA, WATARU FUKUOKAYA, ATSUHIKO YOSHIZAWA, MASANOBU SARUTA, MAMORU HASHIMOTO, TAKAFUMI MINAMI, YUTAKA YAMAMOTO, MORITOSHI SAKAMOTO, KAZUKI NISHIMURA, RYOICHI MAENOSONO, TAKUYA TSUJINO, YUKI YOSHIKAWA, FUMIHIKO URABE, KEIICHIRO MORI, TAKAFUMI YANAGISAWA, SHUNSUKE TSUDUKI, KIYOSHI TAKAHARA, TERUO INAMOTO, KAZUTOSHI FUJITA, TAKAHIRO KIMURA, HARUHITO AZUMA and KAZUMASA KOMURA

Anticancer Research October 2025, 45 (10) 4575-4583; DOI: https://doi.org/10.21873/anticanres.17803
Open Access
Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
NOBUKI FURUBAYASHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, YUSHI FUJIMOTO, MOTONOBU NAKAMURA and TAKAHITO NEGISHI

Anticancer Research May 2025, 45 (5) 2185-2193; DOI: https://doi.org/10.21873/anticanres.17592
Open Access
Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, YOOHYUN SONG, KENICHI HARADA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO, MOTONOBU NAKAMURA and Uro-Oncology Group in Kyushu (UROKYU)

Anticancer Research August 2024, 44 (8) 3409-3417; DOI: https://doi.org/10.21873/anticanres.17161
Open Access
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research August 2024, 44 (8) 3419-3426; DOI: https://doi.org/10.21873/anticanres.17162
Open Access
Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, YOOHYUN SONG, KENICHI HARADA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO, MOTONOBU NAKAMURA and Uro-Oncology Group in Kyushu (UROKYU)

Anticancer Research July 2024, 44 (7) 3025-3032; DOI: https://doi.org/10.21873/anticanres.17115
Open Access
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World
AKINORI MINATO, RIEKO KIMURO, DAICHI OHNO, KENTAROU TANIGAWA, KEISUKE KURETAKE, TAKUO MATSUKAWA, TOMOHISA TAKABA, KAZUMASA JOJIMA, MIRII HARADA, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, KENICHI HARADA, NAOHIRO FUJIMOTO and HIROSHI MIYAMOTO

Anticancer Research September 2023, 43 (9) 4055-4060; DOI: https://doi.org/10.21873/anticanres.16594

Main menu

User menu

Search

Enfortumab vedotin